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Abstract
Background: Nodding syndrome is a neurological disease with no known cure or treatment, impacting children
aged 3–18 years old, mainly in East Africa. Children progressively develop varying degrees of cognitive impairment
which may lead to severe wasting, a vegetative state and, eventually, death. Despite its 50-year existence, little is
known about its cause, risk factors and prognosis. It is a disease where markets will not provide solutions because
the patients are both too few and too poor, making it especially neglected. Open source innovation has been
recommended as an approach to neglected disease research in order to maximize available funding through
greater collaboration and openness to results. Nodding syndrome is a useful case to examine the relevance of
open source innovation.
Methods: We assessed the magnitude of research related to nodding syndrome, its availability, financing and
the amount of collaboration. We surveyed researchers regarding their motivations, attitudes toward open source
innovation concepts and barriers to greater collaboration.
Results: Little research is occurring for nodding syndrome, but it is openly available and researchers are highly
collaborative. The disease is largely unknown, which is partly attributed to WHO not classifying nodding syndrome
as a neglected tropical disease and not including it in any formal programme. Impacted countries, particularly
Uganda, demonstrate a strong degree of ownership through both authorship and research financing. Nodding
syndrome researchers have been allocated a total of €5 million from 2013 to 2019 in grant funding. Annual
financing, due to three new grants, doubled from 2014 to 2015.
Conclusions: Nodding syndrome, a disease previously ignored by the international community, is starting to
receive greater attention, although financing remains modest. If infectious, a larger epidemic could take the world
by surprise. Open source innovation can likely help by sharing research protocols (to avoid duplication) and early
research results (to adjust to the findings of others). The existing scientists have already endorsed open source
innovation, but increased financing is needed. The support of just a few high-income countries could reap a large
impact.
Keywords: Market failures, Nodding syndrome, Neglected tropical diseases, Open knowledge innovation,
Open science, Open source drug discovery, Open source innovation
Background
Nodding syndrome (NS) is a neurological disease of un-
known pathogenesis occurring primarily in East Africa,
where a previously healthy child, typically aged between
3 and 18 years, experiences head nodding episodes
potentially combined with epileptic seizures [1-3]. The
episodes may be triggered by cold temperatures or food
[4,5]. During the episodes children lose contact with
their surroundings, which can be fatal if close to a cook-
ing fire or deep water source. Some parents have
resorted to protecting their children by tying them to
trees [6]. Children progressively develop varying degrees
of cognitive impairment which may lead to severe wast-
ing, a vegetative state and, eventually, death [1,4,7].
There is no known cure or agreed treatment regimen
despite the disease having been recognized for more
than 50 years [5,8,9]. It is unknown if NS is
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infectious (it is clustered within families and regions
[4]), genetic, related to onchocerciasis (most affected
children are infected with Onchocerca volvulus) or
measles, war, malnourishment, fungal contamination
of food, or a combination of these factors [1,9].
Children are treated symptomatically with antiepilep-
tic drugs, with unclear benefit [4]. Due to the un-
known origin of the disease, patients and caregivers
are often stigmatized [6].
The disease is contained to three low-income coun-
tries (South Sudan, Tanzania and Uganda), although it
may also be present in other onchocerciasis-endemic
areas [5,10]. Additionally, it impacts relatively few chil-
dren (i.e. tens of thousands), with the actual prevalence
difficult to ascertain since there is no formal reporting of
cases. In northern Uganda, between 2012 to 2013,
during which time there was an epidemic of nodding
syndrome, there were an estimated 6.8 probable cases of
NS per 1,000 children [11]. By contrast, in Tanzania, NS
appears to be stable and endemic [2].
During 2012–2013, WHO convened three separate ini-
tiatives important to NS. Firstly, with the epidemic of
NS in Uganda creating a greater focus on the disease,
WHO, in collaboration with the Ugandan Ministry of
Health and the United States’ (US) Centers for Disease
Control and Prevention (CDC), convened the first scien-
tific meeting on NS in Kampala in 2012 [12]. A formal
definition of the disease was devised, and a collaborative
research framework was agreed. WHO was tasked with
coordinating collaborative research, including updating
stakeholders on research planning, implementation and
emerging results.
Secondly, in 2013, WHO published its ‘2020 Road-
map on NTDs’ [13] focused on 17 priority, neglected
tropical diseases, but did not include NS. Rather, NS
was classified on WHO’s website as one of seven
“other neglected conditions” and not displayed on the
same webpage as the 17 priority neglected tropical
diseases.
Finally, WHO’s Consultative Expert Working Group on
Research and Development: Financing and Coordination,
delivered its report in 2012 [14], issuing recommendations
on how to increase research and development (R&D) of
diseases that largely impact developing countries, i.e. dis-
eases like nodding syndrome. One of its recommendations
was to encourage open source innovation, that is, the
sharing of research results and innovations freely without
legal or contractual restrictions or payment in a collabora-
tive, typically virtual environment [14]. The rationale
behind open source innovation is that greater collabor-
ation will lead to cost savings in the form of less adminis-
tration and avoidance of duplicative research as well as
the creation of a dynamic collaboration where new ideas
and perspectives can be heard [15, 16].
NS is a textbook example of where markets fail to pro-
vide solutions due to insufficient profit potential. In the
case of nodding syndrome, there are not only too few
patients, but they are also located only in low-income
countries. This is a case where open source innovation
could be advantageous in order to maximize the R&D
financing available.
In this paper, we evaluate NS R&D against ‘open’ R&D
approaches, by examining the following questions:
 Are NS research results (both data and biomedical
samples) openly available?
 Is NS research performed collaboratively and what
are scientists’ and organizations’ motivations for
participation?
 How much financing does NS research receive?
 What are the barriers to greater research
collaboration?
Methods
In an attempt to identify all NS research (ongoing and
complete), we examined publications, clinical trials and
patents. On February 6, 2015, we extracted all research
articles from PubMed that contained either ‘nodding
syndrome’ or ‘nodding disease’ (n = 34). Since so few
articles were retrieved, a Google Scholar search for ‘nod-
ding syndrome’ was performed on May 5, 2015, with
many more results (n = 176), including news items, cita-
tions, conference announcements as well as unrelated
research. After reviewing these items, the relevant
research articles were mostly duplicates (n = 33) with 16
additions. From these cumulative articles (n = 50), we ex-
tracted data about the co-authors, the funding sources
and whether the article was available open access.
Corresponding authors (n = 26) were asked to complete
an online survey (see Appendix) which included the re-
searcher’s motivations for performing NS research, his/her
employer’s perceived motivation, use of patents, availabil-
ity of biological samples as well as perceptions regarding
open source innovation concepts. In the invitation to
participate in this survey, respondents were assured that
all survey results would be held strictly confidential; that
participation was completely voluntary and had no impact
on any interaction with the Norwegian Institute of Public
Health or the Norwegian government; and that the final
article would be shared with respondents and published in
an open access journal. A 62% (n = 16) survey response
rate was achieved. Two follow-up questions were sent via
e-mail. The first was sent directly to the 16 respondents
asking for greater elaboration regarding barriers to NS
research; nine responded. The second follow-up question
was sent in February 2016 to all invited participants of the
Gulu 2015 conference (n = 32), asking researchers to
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identify their financing sources and amounts; 11 responses
were received.
On February 26, 2015, we queried WHO’s Inter-
national Clinical Trials Registry Platform (http://apps
.who.int/trialsearch/) for all clinical trials related to the
condition ‘nodding syndrome’ (n = 1). On February 26,
2015, we searched the World Intellectual Property Orga-
nization’s Patentscope (https://patentscope.wipo.int) for
patents which contained the word ‘nodding syndrome’
and/or ‘nodding disease’; no patents were identified.
To determine funding patterns of grant recipients of
neglected disease R&D, we classified those institutions
receiving financing in 2013 as reported by G-FINDER
[17] as either high-, medium- or low-income utilizing
World Bank country income classifications.
We sought approval for our research portfolio from
the Norwegian Committees for Medical and Health Re-
search. The Committee decided that our research did
not require their ethical approval since we were studying
collaboration amongst scientists and not patients.
Results
Open research
There is very little research in total about NS. Only 50 re-
search articles were found, the oldest article being from
2008. This is likely due, in part, to no common name be-
ing determined for the disease prior to 2012. However,
searches for ‘nodding disease’ did not increase the number
of articles retrieved. This, combined with the registry of
only one clinical trial (a randomized trial of oral pyridox-
ine and conventional anti-epileptic therapy initiated in
2012 and financed by the CDC in collaboration with the
Ugandan Ministry of Health [18]), points to the reality
that little research is occurring for NS.
Encouragingly, though, the published research that
does exist is open access (86%; n = 44), meaning that it
can be read online without charge. Overall, 63% of sur-
vey respondents collected biological samples and 60% of
these are available to other researchers. Not surprisingly,
given the little to no market potential, no patents related
to NS were identified and survey respondents confirmed
that there are no future patent plans.
Collaboration
The 50 articles were exclusively written by public sector
individuals (by academicians, governmental employees
or private citizens). Authorship of the research articles
was highly concentrated. Five corresponding authors
wrote almost half (n = 23) of all of the research articles.
Three of these authors gave a Ugandan affiliation
(although one is German). Overall, 75% (n = 38) of the
articles included at least one author from South Sudan,
Tanzania or Uganda. Nine articles were solely authored
by impacted country researchers.
The articles demonstrated significant collaboration.
Over half (n = 31) of the articles included authors from
more than one continent. Six articles included a co-
author from WHO. Almost all respondents found their
collaborating researchers through personal or profes-
sional networks.
In total, 81% of respondents were still performing
research for NS at the time of the survey and 75%
planned to continue. They were motivated by the in-
tellectual stimulation of NS research (75%), improving
the world to find a cure (69%), and networking with
fellow researchers (63%). Employers were thought to
be motivated by their mandate to advance knowledge
creation (83%).
When asked about utilizing a research-sharing online
platform, respondents were positive (75%) about placing
their ongoing summarized research results or working
papers there, with almost unanimity (92%) stating that
the main benefit would be access to early research
results. There was also near consensus amongst survey
respondents that such a platform would help them to
identify research gaps (81%), become aware of other on-
going research projects (75%) and reduce any potential
duplication of efforts (75%).
One of the recommendations from the 2012 WHO
meeting was for WHO to establish a Nodding Syndrome
Research Coordination Group including a mechanism to
ensure that this type of registry data is shared. Neverthe-
less, we found no evidence that WHO has made any
progress on these recommendations. However, inde-
pendently, two articles were published in 2015 outlining
the research needs for NS [1,5]. Additionally, a scientific
meeting focused solely on NS occurred in Uganda in
July 2015 [9]. This meeting, convened by Uganda’s Gulu
University, gathered 80 participants from four continents
to present and discuss their research results on NS [9].
Financing
In 2015, NS received approximately €1.3 million in
financing, solely from public sector bodies, including the
European Union, the Dutch government and the US
National Institutes of Health. This is a substantial increase
from previous amounts, with approximately €580,000 in
2014 and under €100,000 in previous years. At least six
authors stated that they had not received any funding for
their NS research prior to 2014. Financing is expected to
remain relatively stable, with €1.2 million in 2016 and €1
million in 2017. In total NS will receive at least €5 million
in financing from 2013 to 2019.
Barriers
Survey respondents repeatedly mentioned that obtaining
financing is one of the largest barriers to performing NS
research. They expressed the main difficulties in
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attracting funding is that NS is not considered a funding
priority or a public health threat as well as that the dis-
ease is simply unknown. They asserted that WHO facili-
tates this unawareness by not including it in WHO’s
formal programme for neglected tropical diseases.
That 10 out of the 26 unique corresponding authors
represent institutions located either in Uganda or South
Sudan may also contribute to the difficulties of securing
R&D funding. In an analysis of G-FINDER data for
2013, we found that 81% of grant recipients focusing on
basic research for neglected diseases (n = 1,049) are lo-
cated in high-income countries as opposed to 2% (n
= 29) in low-income countries (utilizing World Bank
country income classifications). If viewed in terms of
funding allocations, 85% (USD 650m) of basic research
financing is paid out to high-income country recipients as
opposed to 1% (USD 9.7m) to those in low-income coun-
tries (Table 1) [19]. Of course, this may be misleading as
low-income country recipients are often subcontractors to
high-income country institutions.
Discussion
The results of this paper demonstrate that NS research
is being performed in an open, collaborative way with
the main barrier being the lack of financing. However,
there are a number of limitations to this study. Firstly,
the financing amounts may be understated since two im-
portant financers did not respond to our query. There
may be additional research articles where NS is identi-
fied as another disease since the official name was only
agreed upon in 2012. Since the number of researchers
identified for NS is small, our dataset also represents a
small sample size. We also did not probe into any con-
cerns that researchers may have regarding collaborative
models and data-sharing. However, we believe that, des-
pite these limitations, our findings have merit.
The premise of open source innovation is that freely
sharing research results and innovations without legal
restrictions or payment will encourage greater collabor-
ation, save administration costs and avoid duplication of
efforts. This is especially relevant for a disease like NS,
with relatively small numbers of affected children lo-
cated in some of the poorest countries of the world. It is
imperative to avoid duplication of research on this
vulnerable population.
Despite its historical connections with the software
industry, an open source approach does not necessar-
ily need to be technical. Rather, an open approach
focuses on access to early research results and the
creation of a collaborative environment. The primary
NS researchers have already agreed to these principles
at their 2012 scientific meeting, and the majority
reconfirmed their willingness in our survey. They are
living up to their pledges by ensuring transparency
through open access publishing and sharing prelimin-
ary research results at the 2015 scientific meeting [9].
Nevertheless, a greater number of researchers is likely
needed to find solutions.
Collaboration on basic research is needed by epide-
miologists, entomologists, ecologists, hydrologists,
experts in onchocerciasis vector control, clinicians,
anthropologists, public health experts, national and
local authorities, and the local population itself [1].
This increased collaboration cannot be achieved if NS
remains unknown, the principle barrier given to
greater research collaboration. WHO may have re-
cently assisted in this regard. In 2015, NS was classi-
fied on WHO’s website as one of seven “other
neglected conditions”, and it was not displayed on the
same webpage as the 17 priority neglected tropical
diseases. In 2016, it is now classified by WHO as an
emerging disease under emergencies preparedness and
response [20], although it is not included in WHO’s
list of top emerging diseases likely to cause major
epidemics [21]. An inclusion in the list of emerging
diseases with potential epidemic ramifications will
likely gain greater attention to NS. Additionally, the
large increases in financing should generate more
research, which will also add to the public awareness
of the disease.
Financing for NS is still relatively modest though,
with annual financing of about €1 million. Compara-
tively, in 2013, Buruli ulcers (with about 6,000 re-
ported annual cases [22]) received USD 7 million for
R&D and human African trypanosomiasis (sleeping
sickness; with about 7,000 reported annual cases [23])
received USD 39 million [17]. G-FINDER, an annual
report that tracks R&D financing for neglected dis-
eases, should also be encouraged to monitor the R&D
financing devoted to NS. This would also improve
awareness of the disease.
Impacted countries, particularly Uganda, demonstrate
a strong degree of ownership through both authorship
and research financing. This may contribute to insuffi-
cient research financing since donors are more likely to
grant funds for neglected disease research to high-
income country recipients.
Table 1 Recipients for basic research for neglected disease
grants in 2013 [19] using World Bank income classifications
Income group Number of grants (%) Sum of grants (%)
Low 29 (2%) USD 9,729,342 (1%)
Lower middle 62 (5%) USD 19,329,460 (3%)
Upper middle 118 (9%) USD 33,397,384 (4%)
High 1049 (81%) USD 649,722,068 (85%)
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Conclusions
It is unlikely that greater collaboration can be achieved
without greater financing. Open access journals and par-
ticipation in scientific meetings are generally not free.
Today, NS research is underfunded to the extent that it
relies upon researchers using their own personal funds.
This is neither sustainable nor the path to finding a cure.
Ideally, several high-income governments would cham-
pion the disease. This is an opportunity where a rela-
tively modest investment could reap a large impact.
Uganda is already demonstrating significant country
ownership here. High-income countries could pledge a
matching grant, for example, on a scale of 10 times in-
vestment for every dollar invested by an impacted
country.
There will likely never be a viable business model to
find a cure for NS. The costs of developing a vaccine,
new medicine or diagnostic, or eradicating a parasite are
large [24,25]. There is little to no revenue to be had,
unless it is perceived as a global threat. Solving this
problem, therefore, is the responsibility of governments
(both impacted countries and donors) as a global public
good. Maintaining the current level of openness and
collaboration (but increasing the scale of researchers)
should make these public investments efficient by focus-
ing them on the research and avoiding administrative
costs, like patenting and contracting.
The Ebola and Zika virus crises have awakened the
global community to seemingly small, rural, public
health threats. So much is unknown about NS that
new epidemics, like the one in Uganda from 2006 to
2013, could take countries and the world by surprise.
Most brutally, the current apathy toward NS is slowly
destroying the lives of previously healthy children
while forcing their families to stand helplessly by and
watch.
Appendix
Survey to nodding syndrome corresponding authors




 I have never performed research on nodding
syndrome (Go to end)
2. How many years have you performed research on
nodding syndrome?




 I don’t know
4. What is your personal motivation for performing
research on nodding syndrome? (Please check all
that apply)
 I find research on nodding syndrome
intellectually stimulating and scientifically
interesting
 I believe that performing nodding syndrome
research will assist the progression of my career
 I am interested in being a part of a network of
nodding syndrome researchers
 My family/friends are at risk from nodding
syndrome; I want to make a difference in their
lives
 I want to improve the world by doing my part to
find a cure for nodding syndrome
 I did not select nodding syndrome as my field of
research – my employer has as a part of my duties
 I perform nodding syndrome research because
that was the funding that I was able to secure
 Other (free text field)
5. What type of organization is your employer?
(Please select the one that best applies)
 A university or college
 A government research institute
 A for-profit company (for example, a pharma-
ceutical company)
 A private non-profit research institute
(for example, foundation-based)
 I am self-employed (Go to Question 7)
 I am unemployed (Go to Question 7)
 I am retired (Go to Question 7)
 I am a student (Go to Question 7)
 Other (free text field)
6. What do you believe is your employer’s motivation
for performing nodding syndrome research? (Please
check all that apply)
 My employer is a publicly-funded institution
with a mandate to advance knowledge creation
 My employer believes that there is a potential
profit in researching nodding syndrome
 My employer believes that it has a social
responsibility to research nodding syndrome in
order to improve health in low-income
countries
 There is external funding readily available to
perform nodding syndrome research
 My employer educates students regarding
neglected diseases and therefore my research
assists in the students’ formal education
 My employer is located in a nodding syndrome-
endemic country, and it is a national priority to
research nodding syndrome
 My employer leaves my field of research up to
my own discretion
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 My nodding syndrome research activities are not
a part of my paid job
 Other
 I don’t know
7. Have you or your organization applied for any
patents on your nodding syndrome research, or
plan to apply for patents on your nodding
syndrome research?
 Yes (Go to Question 8)
 No (Go to Question 10)
 I/we have not yet decided (Go to Question 8)
 I do not know (Go to Question 10)
 My research is not patentable (Go to Question 10)
8. What stage would you designate the research that
you have patented or plan to patent? (Please select
the one that best applies)
 Basic research (i.e. research into the mechanisms/
organisms that cause nodding syndrome)
 Target identification and validation
 Finding and optimizing lead compounds
 Developing processes for making candidate
drugs, vaccines or diagnostics
 Clinical trials
 Other
 None of the above
 I don’t know
9. Why did you or will you patent your research
results on nodding syndrome? (free text)
10. Did your research collect any biological samples
(i.e. blood specimens, etc.)?
 Yes (Go to Question 11)
 No (Go to Question 12)
 I don’t know (Go to Question 12)
11. Have you made these specimens available to
external researchers, for example, through a
biobank or other repository?
 Yes
 No
 I don’t know
12. Did your research generate any chemical or
molecular compounds?
 Yes (Go to Question 13)
 No (Go to Question 14)
 I don’t know (Go to Question 14)
13. Have you made these compounds available to




 I don’t know
14. As identified through PubMed, only 29 research
articles have ever been published on nodding
syndrome or nodding disease. How did you find
your collaborating partners? (free text)
15. Since there are so few researchers focused on
nodding syndrome, do you believe that master
degree students could be one potential source of
additional research capacity? Please describe why
or why not and if so, which academic fields
would be particularly valuable (free text)
16. One area that we are considering is the helpfulness
of registries of previous and ongoing research,
particularly related to neglected diseases. The idea
is that research projects would be registered once
they are funded or started. Therefore, in theory, you
could be alerted to specific, newly initiated research
projects in a topic of your choice.
What could be the benefits of a registry covering all of
nodding syndrome research? (Please check all that
apply)
 The registry could help me to become aware of
related research projects
 The registry could help me to identify gaps
within my field of research
 The registry could help me to determine my
future research projects
 The registry could help me to identify potential
collaborators for my research
 The registry could reduce duplication of research
 Other (free text field)
 I do not see any benefits of such a registry
 I don’t know
17. We are also examining the potential of placing
preliminary research results on a publicly-available
website for comment or review. Prominent journals
have indicated that sharing research results in this
fashion is acceptable and do not preclude the
research from later publication.
Would you consider sharing your preliminary research
results on nodding syndrome on a publicly-available
website?
 Yes (Go to Question 18)
 No (Go to Question 20)
 I don’t know (Go to Question 20)
18. What types of results might you be willing to share?
(Please check all that apply)
 Raw results data
 Summarized results data
 Working papers in development
 Other (free text field)
 I don’t know
19. What would be the benefit of sharing research
results? (Please check all that apply)
 Giving access to early research results
 Commenting on others’ research
 Establishing research collaboration
 Other (free text field)
 I don’t know
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20. Do you have additional ideas on how research on
nodding syndrome can be strengthened internationally,
e.g. through collaboration and coordination, financing,
or other means? (free text)
21. Do you have any additional comments? (Free text)
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